We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+22.52%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$312M
AUM Growth
+$29.5M
Cap. Flow
-$9.09M
Cap. Flow %
-2.91%
Top 10 Hldgs %
68.33%
Holding
49
New
15
Increased
5
Reduced
3
Closed
14

Top Buys

Rank Stock Value
1
ABLX
Ablynx NV
ABLX
+$9.48M
2
FENC icon
Fennec Pharmaceuticals
FENC
+$8.45M
3
CRSP icon
CRISPR Therapeutics
CRSP
+$5.34M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$4.41M
5
LOXO
Loxo Oncology, Inc
LOXO
+$3.86M

Top Sells

Rank Stock Value
1
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$9.25M
2
CTMX icon
CytomX Therapeutics
CTMX
+$8.18M
3
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$7.75M
4
TBPH icon
Theravance Biopharma
TBPH
+$6.16M
5
SYBX
Synlogic
SYBX
+$4.75M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
2 Communication Services 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CMRX
26
DELISTED
Chimerix, Inc.
CMRX
$2.78M 0.89%
600,000
-803,000
-57% -$3.82M
VKTX icon
27
Viking Therapeutics
VKTX
$3.95B
$1.95M 0.62%
+480,558
New +$1.4M
QURE icon
28
uniQure
QURE
$3.44B
$1.78M 0.57%
+90,801
New +$1.38M
QTRX icon
29
Quanterix
QTRX
$125M
$1.4M 0.45%
+65,000
New +$1.27M
ACHN
30
DELISTED
Achillion Pharmaceuticals
ACHN
$1.27M 0.41%
+440,000
New +$1.6M
PLX icon
31
Protalix BioTherapeutics
PLX
$210M
$1.21M 0.39%
+182,500
New +$1.23M
RYTM icon
32
Rhythm Pharmaceuticals
RYTM
$7.75B
$1.11M 0.36%
+38,300
New +$1.01M
SYRS
33
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$720K 0.23%
7,407
-4,250
-36% -$571K
SPPI
34
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$587K 0.19%
+31,000
New +$562K
BLRX
35
BioLineRX
BLRX
$12.1M
$272K 0.09%
417
– –
CTMX icon
36
CytomX Therapeutics
CTMX
$745M
– –
-450,000
Closed -$8.18M
ENTA icon
37
Enanta Pharmaceuticals
ENTA
$402M
– –
-100,000
Closed -$4.68M
INSM icon
38
Insmed
INSM
$26.5B
– –
-120,000
Closed -$3.75M
RNAC icon
39
Cartesian Therapeutics
RNAC
$302M
– –
-3,167
Closed -$1.73M
SYBX
40
DELISTED
Synlogic
SYBX
– –
-16,667
Closed -$4.75M
TBPH icon
41
Theravance Biopharma
TBPH
$885M
– –
-180,000
Closed -$6.16M
EGRX
42
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
– –
-130,000
Closed -$7.75M
DCPH
43
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
– –
-217,000
Closed -$4.12M
ICPT
44
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-28,400
Closed -$1.65M
QUOT
45
DELISTED
Quotient Technology Inc
QUOT
– –
-110,000
Closed -$542K
MNTA
46
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
– –
-500,000
Closed -$9.25M
ARQL
47
DELISTED
Arqule Inc
ARQL
– –
-1,220,000
Closed -$1.35M
PETX
48
DELISTED
Aratana Therapeutics, Inc.
PETX
– –
-420,000
Closed -$2.57M
NDRM
49
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
– –
-70,000
Closed -$2.72M
1
2

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q4 2017 Portfolio in Review

As of Q4 2017, Opaleye Management held 49 positions worth $312M, up 10% from $283M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Opaleye Management's Q4 2017 filing shows 15 new, 5 increased, 3 reduced and 14 closed positions. Its largest new stake was Ablynx NV: 420,000 shares worth $10.5M. The largest sale was Momenta Pharmaceuticals, Inc., an estimated $9.25M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Communication Services.

  • Opaleye Management's largest Q4 2017 buy was Ablynx NV: 420,000 shares worth $10.5M.
  • Opaleye Management added most to Loxo Oncology, Inc in Q4 2017, an estimated $3.86M increase.
  • Opaleye Management's biggest Q4 2017 reduction was Chimerix, Inc., cutting an estimated $3.82M.
  • Opaleye Management fully exited Momenta Pharmaceuticals, Inc. in Q4 2017, selling an estimated $9.25M.
  • Opaleye Management's ten largest holdings make up 68% of its $312M portfolio in Q4 2017.
  • Opaleye Management opened 15 new positions and closed 14 in Q4 2017.
  • Opaleye Management's portfolio value rose 10% quarter-over-quarter to $312M.

Based on Opaleye Management's 13F filing for Q4 2017, filed 9 Feb 2018.